Leucid Bio provides business update and outlook for 2023

  • Proprietary Lateral CAR Platform achieved pre-clinical proof-of-concept data demonstrating prolonged disease-free survival compared to other CAR T-cell products.

  • Lead programme, LEU011 has completed pre-clinical development for the treatment of solid tumours and is in pre-clinical development for a range of haematological malignancies.

  • Leucid expects to file its CTA to initiate the clinical trial in H1 2023 and to be dosing patients by H2 2023.

  • Bolstered Senior Leadership team and restructured Executive Team to prepare the Company for its next phase of growth.

  • Achieved Innovative Licensing and Access Pathway (ILAP) status enabling an accelerated time to market, facilitating patient access to medicines.

London, UK – 16 February 2023 – Leucid Bio (“Leucid” or the “Company”), a biotech company pursuing a differentiated approach to develop next generation Chimeric Antigen Receptor T-cell (CAR-T) therapies using the Company’s proprietary Lateral CAR Platform to improve treatment outcomes and save the lives of patients with refractory cancers, today provides a business update.

Read more…